Skip To Main Content
Prithviraj Bose on Muck Rack

Prithviraj Bose

As seen in: Color Research & Application, Nature, Wiley, Wiley Online Library, Educational Studies, MDPI, Medscape, Cell Press, Journal of Clinical Oncology, Blood and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Prithviraj

Contact Prithviraj, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial

|
By S’ Disclosures, Prithviraj Bose, Haris Ali
| Journal of Clinical Oncology Verified
1,2 Despite therapeutic advances, MF remains associated with substantial morbidity and reduced survival.3 Myelofibrosis (MF) is a hematologic malignancy characterized by aberrant proliferation of myeloid progenitor cells, resulting in progressive bone marrow fibrosis, splenomegaly, and substantial symptom burden.Despite therapeutic advances, MF remains associated with substantial morbidity and reduced survival.
Open in Who Shared Issue with article?

European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis - Blood Cancer Journal

|
By Monia Marchetti, Alessandro Vannucchi, John Mascarenhas, Alberto Alvarez-Larran, Prithviraj Bose, Robert Peter Gale, Claire Harrison, Steffen Koschmieder, Alessandro Rambaldi, Ayalew Tefferi
| Nature Verified
Abstract Most myelofibrosis (MF) drug approvals by Health Authorities are based on 1 or 2 outcome measures such as spleen volume reduction and/or improved quality of life. This 1–2 dimensional approach fails to capture the clinical complexity of MF. A European LeukemiaNet (ELN) task force developed a composite endpoint that allows multiple outcomes to be simultaneously measured.
Open in Who Shared Issue with article?

Managing and Understanding Toxicities Associated With Myelofibrosis Therapy

|
By Prithviraj Bose
| ONCOLOGY journal Verified
CancerNetwork® spoke with Prithviraj Bose, MD at the Society of Hematologic Oncology 2025 Annual Meeting following a presentation he delivered titled “Individualizing Treatment Selection for [myelofibrosis]”. During the discussion, he considered the toxicities that different myelofibrosis treatments may elicit. With ruxolitinib (Jakafi), an FDA-approved JAKinhibitor, anemia, thrombocytopenia, weight gain, shingles, and non-melanoma skin cancer are all adverse events that patients may experience.
Open in Who Shared Issue with article?
See all 44 licensed articles (105 Total)